Abstract:The purpose of the research is to examine the advantages and difficulties of target-site drug delivery methods, with an emphasis on the application of polyethylene glycol (PEG) to enhance drug solubility, bioavailability, and immune response characteristics. It has been demonstrated that this method lowers immunogenicity, enhances pharmacokinetics, and helps drugs pass the blood-brain barrier while reducing reticuloendothelial system clearance. PEG and its derivatives are being used more and more to alter therapeutic substances, offering an escape from some of the drawbacks of conventional medication formulations. In the review, different PEGylation tactics are examined, including cutting-edge methods for reversing multi-drug resistance in nanocarriers. PEGylation has a number of benefits, but there are still drawbacks, including the immunogenic reaction to PEG, which is sometimes referred to as "anti-PEG antibodies," and stability problems that call for the creation of countermeasures. The study devotes a large amount of its space to listing FDA-approved PEGylated medications, emphasizing their therapeutic advantages and clinical uses in a range of medical specialties. The research also explores the regulatory environment that surrounds PEG, closely examining its effectiveness and safety in medication compositions. The review goes beyond PEGylation and includes lipid-based nanocarriers, including liposomes, nanostructured lipid carriers (NLCs), and solid lipid nanoparticles (SLNs). Because these nanocarriers can target specific tissues or cells, improve bioavailability, and encapsulate pharmaceuticals, they are becoming more and more significant in drug delivery systems. The Target Product Profile (TPP) and Quality by Design (QbD) principles serve as the foundation for the creation and characterization of these lipid-based systems. These tools direct the methodical assessment of material properties and risk assessments during the formulation phase. This method guarantees that the finished product satisfies the appropriate requirements for efficacy, safety, and quality. The regulatory status and safety profile of nano lipid carriers are covered in the paper's conclusion, which emphasizes the importance of careful examination and oversight in bringing these cutting-edge products to market. Overall, this thorough analysis highlights the revolutionary potential of lipid-based nanocarriers and PEGylation in improving drug delivery and therapeutic efficacy, but it also draws attention to the continued difficulties and legal issues that need to be resolved in order to fully reap the benefits of these technologies in biomedicine.

Biodegradable zwitterionic polymers as PEG alternatives for drug delivery

Zwitterionic Polymer: A New Paradigm for Protein Conjugation beyond PEG

A Novel Zwitterionic Copolymer with A Short Poly(Methyl Acrylic Acid) Block for Improving Both Conjugation and Separation Efficiency of A Protein Without Losing Its Bioactivity

Zwitterionic polymers: addressing the barriers for drug delivery

Poly(ethylene Glycol) Alternatives in Biomedical Applications

Recent Advances in Peptide Engineering of PEG Hydrogels: Strategies, Functional Regulation, and Biomedical Applications

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Preparation, Characterization and Degradation Characteristics of Polyanhydrides Containing Poly(Ethylene Glycol)

Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers

Recent advances in the bioanalytical methods of polyethylene glycols and PEGylated pharmaceuticals

Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system.

Emerging trends of discrete Poly(ethylene glycol) in biomedical applications

PEG Based Hyperbranched Polymeric Hollow Nanospheres

To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

High Molecular Weight Biodegradable Poly(Ethylene Glycol) Via Carboxyl-Ester Transesterification

Synthesis of degradable functional poly(ethylene glycol) analogs as versatile drug delivery carriers.

PEGylation in Pharmaceutical Development: Current Status and Emerging Trends in Macromolecular and Immunotherapeutic Drugs

Hydrolytically Degradable Zwitterionic Polyphosphazene Containing HEPES Moieties as Side Groups

Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

Biocompatible and biodegradable polymersomes as delivery vehicles in biomedical applications

Anti-PEG Antibodies: Current Situation and Countermeasures